# Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI

Study · id `cardio:ct-nct04347434` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04347434](<https://clinicaltrials.gov/study/NCT04347434>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04347434

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT04347434. Non-randomized; no masking; primary purpose treatment. Start 2020-02-12 (actual); primary completion 2027-11-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT04347434, source copy `cardio:ctgov-nct04347434-2023-11-24`, retrieved 2026-10-26)
- Started: 2020-02-12 (actual) (ClinicalTrials.gov record NCT04347434, source copy `cardio:ctgov-nct04347434-2023-11-24`, retrieved 2026-10-26)
- Primary completion: 2027-11-12 (anticipated) (ClinicalTrials.gov record NCT04347434, source copy `cardio:ctgov-nct04347434-2023-11-24`, retrieved 2026-10-26)
- Completion: 2027-12-30 (anticipated) (ClinicalTrials.gov record NCT04347434, source copy `cardio:ctgov-nct04347434-2023-11-24`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT04347434, source copy `cardio:ctgov-nct04347434-2023-11-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04347434-2023-11-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI
- Acronym: CONTRAST-2
- Condition: Myocardial Infarction, Acute
- Condition: Myocardial Strain
- Condition: Arterial Stiffness
- Condition: Quality of Life
- Intervention (Drug): Atorvastatin 80mg
- Lead sponsor: Penza State University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)

## Provenance

Content hash: 9de9c035e15a18d32888d3361725099b3454fed5aa3d4f32ccbd4b45784d9d01
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
